Modulation of the M2 Muscarinic Acetylcholine Receptor Activity with Monoclonal Anti-M2 Receptor Antibody Fragments

Received for publication, June 28, 2004, and in revised form, October 6, 2004
Published, JBC Papers in Press, October 14, 2004, DOI 10.1074/jbc.M407213200

Jean-Christophe Peter§‡, Gerd Wallukat§, Jean Tugler§, Damien Mauricé‡, Jean-Christophe Roegel§, Jean-Paul Briand‡, and Johan Hoebeke‡***

From the ¥CNRS, Unité Propre de Recherche 9021, Institut de Biologie Moléculaire et Cellulaire, Laboratory of Therapeutic Chemistry and Immunology, F-67084 Strasbourg, France, ¥Max Delbrück Centrum for Molecular Medicine, D-13092 Berlin, Germany, and ¥Forenap Therapeutic Discovery, Institute of Pharmacology, School of Medicine, F-67000 Strasbourg, France

Antibodies directed against the second extracellular loop of G protein-coupled receptors are known to have functional activities. From a partial agonist monoclonal antibody directed against the M2 muscarinic receptor, we constructed and produced a single chain variable fragment with high affinity for its target epitope. The fragment is able to recognize its receptor on Chinese hamster ovary cells transfected with the M2 muscarinic acetylcholine receptor to block the effect of carbachol on this receptor and to exert an inverse agonist activity on the basal activity of the receptor. The antibody fragment is also able to increase the basal rhythm of cultured neonatal rat cardiomyocytes and to inhibit in a non-competitive manner the negative chronotropic effect of carbachol. This antibody fragment is able to exert its inverse agonist activity in vivo on mouse heart activity. The immunological strategy presented here could be useful to develop specific allosteric inverse agonist reagents for G protein-coupled receptors.

The G protein-coupled receptor family is one of the main targets of currently used drugs (1). The M2 muscarinic acetylcholine receptor (M2Ach-R) belongs to this receptor family. This receptor is an integral membrane protein consisting of seven membrane spanning α-helices linked together by extracellular and intracellular loops that form a pharmacophore pocket. One of the pharmacological challenges posed by this family of receptors is the presence of multiple subtypes, all recognizing the same endogenous ligands. This suggests a high conservation of the pharmacophore for a particular family of receptors, thus explaining the difficulty to develop drugs (agonists or antagonists) specific for one of these subtypes. Autoantibodies directed against cardiovascular G protein-coupled receptors functionally interfering with the target have been described in several cardiovascular diseases (2–6). Most of these autoantibodies are directed against the second extracellular loop and are exquisitely specific for one of the receptor subtypes in view of the highly variable sequence of this domain (7). Elies et al. (8) have produced a monoclonal antibody directed against a peptide derived from the N-terminal part of the second extracellular loop of the M2Ach-R. This monoclonal antibody (IgG 2a) displays a partial agonist activity on its target receptor because of its natural bivalency. It can be used to stabilize constitutive active receptor dimers and paradoxically induces a small decrease in carbachol affinity for the M2Ach-R.

In this study, this antibody was used to construct an scFv fragment (single chain variable fragment), which was cloned, sequenced and expressed in Escherichia coli. We describe the immunochemoanalytical, pharmacological, and physiologic properties of this scFv fragment. As reported in a previous study with an inverse agonist scFv-directed against the β2 adrenergic receptor (9) this may open the way to the design of allosteric inverse agonist reagents that are specific for one subtype of receptor.

** Experimental Procedures

Peptides—M2-G19K (GVRTVEDGECYIQFFSNA(K)) peptide and its truncated version V9C (VRTVEDGE) corresponding to the second extracellular loop (residues 167–184) of the human M2Ach-R were synthesized using N-(9-fluorenylmethoxycarbonyl) (Fmoc) chemistry with an automated peptide synthesizer (10). The peptides were purified by high pressure liquid chromatography and their integrity assessed by matrix-assisted laser desorption ionization time-of-flight spectrometry.

Construction of the Single-chain Antibody Gene—The single-chain antibody gene fragment encoding the heavy and light variable region of the monoclonal antibody B8E5 (8) was prepared as described in Ref. 9. scFv B8E5 was created by joining the B8E5 VH and VL genes together by PCR splicing with overlap extensions using oligonucleotides that encoded a 15-amino-acid linker (G4-S)3 between the C terminus of the VH and the N terminus of the VL gene. The ends of the variable gene were modified by PCR using as primers, VHRev (5′-GGTAACGACTCGGCA GGT GTT GCT GCA TGC C-3′), which encodes the N-terminal wild type sequence of the VH containing a PstI site, and VLFor (5′-ACC ACC GGA TCC GGC TCC GCC TGC AAG GAG GCT CTG CT-3′), which encodes the C terminus of the VH and a part of the linker. VHRev (5′-GGTAACGACTCGGCA GGT GTT GCT GCA GGT GTT GCT TCA GGT GGT GGG GCG CTAGT GGT GGT TCG GAG GTA GTG ATG ATG GCC GA-3′) and VLFor, containing a XhoI site that encodes His6 residues (5′-GCA ATG CTA CGA GTG AAT GTG GAT GAT GTG GAT GGT GAT GTT TGA CCA GCT TGG TGC C-3′), were used to amplify and modify the VL gene. The scFv gene was inserted in frame with the PelB sequence on the expression vector pSW1 (11) between the PstI and XhoI sites. The constructed vector pSW1–6His His, was cloned in HB 2151 E. coli strain.

Bacterial Expression of scFv—B8E5—The bacterial expression of the recombinant scFv protein and extraction of soluble periplasmic protein are described in Ref. 12. The periplasmic extract was centrifuged at 10, 000 × g, and the supernatant was filtered on a 0.45-µm membrane (Millipore) and extensively dialyzed against PBS (20 mM NaHPO4, 1.8 mM KH2PO4, 150 mM NaCl, 2.7 mM KCl, pH 7.4).
Production and Purification of Fab Fragments—Monoclonal antibody B8E5 (8) was purified from ascitic fluids on an affinity column made by coupling G19K peptide to CNBr-activated Sepharose by a standard procedure (Amersham Biosciences); the ascitic fluids (2 ml) were diluted 1:20 in PBS, and the antibody, adsorbed on the affinity column in PBS, was eluted with 0.2M glycine, pH 2.7, and immediately dialyzed against PBS.

Fab fragments were obtained by papain (Sigma) digestion (13) of the affinity purified monoclonal antibody B8E5. The Fab fragments were separated from the Fc fragments on a Hi-Trap protein A column with a Gradi-Frac system (Amersham Biosciences) followed by a second affinity chromatography purification. Purity was checked by SDS-polyacrylamide gel electrophoresis. No unhydrolyzed IgG could be detected.

Purification of the scFv Construction—The scFv recombinant antibody fragment was purified from periplasmic extract on a protein-L immobilized Sepharose (Pierce) 1-ml column, and the adsorbed recombinant proteins were eluted with 0.2 M glycine, pH 2.7, and immediately dialyzed against PBS.

Gel Electrophoresis and Western Blot Analysis—SDS-PAGE analysis was performed as a standard procedure using 12.5% acrylamide gels followed by staining with Coomassie Brilliant Blue (Serva) or immunoblotting. For Western blot analysis, the proteins were transferred from the gels onto a PROTRAN Nitrocellulose Transfer membrane (Schleicher & Schuell) using a mini trans-blot system (Bio-Rad) in transfer buffer (25 mM Tris-HCl, 190 mM glycine, 20% methanol, pH 8.3). The membranes were soaked for 1 h in PBS-T (20 mM Na2HPO4, 1.8 mM KH2PO4, 150 mM NaCl, 2.7 mM KCl, pH 7.4) supplemented with 5% nonfat milk powder and 0.1% Tween 20. This was followed by a 1-h incubation with anti-His tag antibody conjugated to horseradish peroxidase (HRP 1/2000) (Sigma). The antibody was diluted in the blocking solution PBS-T milk. The proteins on the membranes were revealed by the classical procedure of the ECL reagents (Amersham Biosciences).

Immunochemical Characterization of the scFv Fragment—The instrument Biacore 3000 and all the reagents for analysis were obtained from Biacore (Uppsala, Sweden). The carboxylated dextran matrix (CM5) was activated with 50 ml of a mixture 0.2 M N-ethyl-N-(3-dimethylaminopropyl)carbodiimide and 0.05 M N-hydroxysuccinimide. For kinetic analysis the G19K peptide was immobilized with the standard Biacore protocol. Kinetic studies were performed as described (14).

Inhibition assays were performed using Biacore technology; the same concentration of scFv B8E5 was preincubated with or without different concentration of V9C or G19K peptides for 30 min and then injected on the sensor chip with high density of V9C peptides immobilized by its C terminus end with standard Biacore procedure. Under this mass trans-
fer condition, the slope of the curves is directly correlated with the active concentration of scFv (15).

Protein Concentration Determination—The total protein concentration of the purified scFv (active + non-active proteins) was determined using the BCA kit (Pierce) and by measuring absorbance at 280 nm. The extinction coefficient was determined using the Expasy program tool available on the Web.2

Immunocytochemistry—CHO human M2Ach-R, M1Ach-R, and M3Ach-R transfected cells (16) (kindly provided by Dr. M Waelbroeck) were fixed for 5 min with 2% paraformaldehyde and permeabilized with PBS and 0.1% Triton X-100 for 1 min. Slides were saturated with PBS supplemented with 5% nonfat dry milk. ScFv B8E5 and scFv 9C2 (control) were incubated for 1 h at room temperature 4 °C. After three washes with PBS, biotinylated protein-L (1/500, Pierce) was added and incubated for 1 h at room temperature. Alexa-conjugated Streptavidin (1/500, Molecular Probes, Junction City, OR) was allowed to react with the fixed primary antibody for 1 h at room temperature. 4’,6-Diamidino-2-phenylindole (1 µg/ml, Sigma) was used for nuclear staining.

Pharmacological Characterization of the scFv Fragment: cAMP Response by M2Ach-R CHO Transfected Cells Treated in Vitro with scFv—The biochemical effects of scFv B8E5 on the M2Ach-R were assessed by measuring the intracellular cAMP concentration of M2Ach-R CHO transfected cells. Cells were seeded in 6-well culture plates 24 h before stimulation and then washed and incubated with 1 ml of Hank’s balanced salt solution buffered with 10 mM HEPES containing 100 µM of isobutylmethylxanthine to block cAMP hydrolysis. After 30 min, scFv was added at different concentrations, and 30 min after the first treatment forskolin and carbachol were added to a final concentration of 1 µM and 30 nM, respectively. Stimulation of the cells was performed during the first 15 min, and then the supernatant was aspirated and the reaction was stopped by adding 1 ml of boiling water. The cAMP content was determined using a competitive immunoenzymatic assay (Biotrak cAMP, Amersham Biosciences). The protein concentrations of the samples were determined using a BCA kit (Pierce). The concentra-

---

2 Personal communication, www.expasy.org/tools/protparam.html.
tion of cAMP was reported on the protein concentration related to the number of cells/well; the results were expressed as pmol cAMP/mg protein. Results are from duplicates of three independent experiments.

Beating Frequency of Neonatal Rat Cardiomyocytes in Culture—Rat neonatal cardiomyocytes were prepared from ventricles of 1–2 day-old Sprague-Dawley rats using a modified method (18). The cells were cultured as monolayers for 8 days at 37 °C in SM20–1 medium (32) supplemented with 10% heat-inactivated calf serum and 2/μM fluoro-deoxyuridine and exhibited a spontaneous basal pulsation rate of 160 ± 20 beats/min. The cardiomyocyte cultures were washed with fresh medium containing serum and incubated for 2 h at 37 °C with the same medium under stationary conditions. The flasks were transferred to the heatable stage of an inverted microscope, reagent was added, and the increase of the beating rate was determined for at least 10 observations for each experimental point in three independent experiments.

Physiological Characterization of the scFv Fragment in Vivo on Mice—Twelve male BALB/c mice (20 g each) were given tail intravenous injections while being kept in individual mouse ECG boxes as described in Ref. 19 for four continuous weeks. The ECG boxes (Rodent Restrainers for ECG, Sesams, Logelbach, France) have four conductive surfaces on their bottom to position the four limbs of the conscious animal. These surfaces are coated with contact gel and connected to analogue amplifiers for signal amplification and filtering (0.5–30 Hz cutoff frequencies; Bessel type filter, order 2; 50 Hz notch filter (−30 db); Sesams, Logelbach, France). The amplified and filtered signals are digitized at 256 Hz on a signal processor board (64 channels, 16-bit resolution) and stored in digital form on a personal computer using the HEM recording software (Notocord, Croissy sur Seine, France).

Three-lead electrocardiograms (DI, DII, DIII derivations) were recorded from 12 conscious mice during 60 min. Mice were not anesthe-
FIG. 3. Biochemical effects of scFv B8E5 on the M2Ach receptor. cAMP accumulation was measured in CHO M2Ach-R transfected cells treated with forskolin (1 μM) and scFv B8E5 in the absence (a) and presence (b) of carbachol (30 nM) or (c) increasing concentration of carbachol (0.3–30 nM). Results are expressed in pmol/mg protein. scFv is able to increase intracellular cAMP upon forskolin stimulation and blocks cAMP decrease in carbachol/forskolin-stimulated cells in a dose-dependent manner. Control scFv 9C2 (dark gray) did not have any significant effects on cAMP accumulation with or without carbachol. The inserted histograms in a and b show stimulation of untransfected CHO cells with 1 μM forskolin (F) and 30 nM carbachol (FC) with or without scFv. The antibody fragment exerts no effect on the cAMP level on CHO untransfected cells. Asterisks show results statistically different from experiments without scFv at p < 0.05 in a Student's t test.
tized to prevent ECG modifications (20). After 20 min in the ECG box, each treatment in a 100-μl volume was injected intravenously (Table I). The plan of the intravenous injection was designed to have a period of 1 day between two injections of carbachol.

The ECG signal was analyzed off line. The QRS complexes were identified, and artifact, ectopic beats, and normal beats were recognized and annotated (ECG-Auto, EMKA Technologies, Paris, France). The heart rate (bpm) was calculated based on the beat per beat data.

Statistics—Statistical analysis was performed using Minitab software. To compare the percent of variation of the cardiac rhythm with the rhythm at \( t = 0 \), we used a Student's paired match \( t \) test to compare the integral of each curve upon the different treatments.

Molecular Modeling—ScFv B8E5 model was built in silico using the Biopolymer, Homology, and Discover software of Accelrys (San Diego, CA). The VH and VL chains of the scFv B8E5 were built from the Protein Data Bank accession codes 1IFH and 2MCP, respectively. The sequences of the templates (see Fig. 6) were changed to those of the scFv B8E5, and the modified chain was submitted to a steepest descent energy minimization of 2000 steps until a root mean square derivative of 0.001 kcal/mol Å was reached. The assembly was again submitted to a conjugate gradient minimization procedure of 2000 steps with the backbone fixed.

Fig. 4. Pharmacological effects of scFv B8E5 on neonatal rat cardiomyocytes in vitro. scFv B8E5 increased spontaneous beating (a) rate and inhibited the carbachol stimulation of neonatal rat cardiomyocytes in a non-competitive manner (b); the decrease in beat number/min is represented by increasing concentration of carbachol in the presence of scFv B8E5 (6 nM (□) and 12 nM (△)) or without co-treatment (●).
RESULTS

Cloning, Sequencing, Expression, and Immunochemical Characterization of the scFv B8E5 Fragment—The N-terminal part of the VH and VL of the B8E5 antibody was sequenced by Edman degradation to design the primers used for the amplification of the two domains. The original sequence of the VH, EVQLVE and the VL, DIVMAQ, helped us to design the VHRev and VLRev primer. The scFv-encoding gene derived from the variable regions (VH and VL linked together via a short linker (G4S3)) of the IgG2a B8E5 monoclonal antibody (8) with addition of a C-terminal His_6 tag encoding sequence, was inserted in frame with the PelB sequence into the pSW1 expression vector. The sequence of the single-chain construction is represented in Fig. 1. We confirmed that the cloned VL gene did not correspond to the aberrant κ transcript of the sp2/0 hybridomas (21) The plasmid pSW1-scFv B8E5 was cloned into the HB2151 E. coli strain, and the recombinant protein was expressed and exported to the bacterial periplasm by its leader sequence PelB (22). The scFv B8E5 was easily purified and concentrated by affinity chromatography (Fig. 2).

Surface plasmon resonance technology allows the analysis of scFv/antigenic peptide interaction in real time. It also allows the determination of the active concentration of analytes in solution (15). The active concentration showed that 100% of the purified recombinant protein was able to interact with the antigenic peptides V9C. The calculated concentration allowed us to determine the kinetic parameters of the scFv B8E5 using a Biacore System and the BIAeval 3.1 software. A Langmuir binding model gave us the following kinetic parameters: the $k_{\text{on}} = 2.4 \times 10^7$ M$^{-1}$ s$^{-1}$, the $k_{\text{off}} = 2.15 \times 10^{-6}$ s$^{-1}$, and the equilibrium constant $K_a = 1.1 \times 10^8$ M$^{-1}$. These parameters are similar to those calculated under the same conditions for the B8E5 proteolytic Fab fragment ($k_{\text{on}} = 7.4 \times 10^5$ M$^{-1}$ s$^{-1}$, $k_{\text{off}} = 4.7 \times 10^{-3}$ s$^{-1}$). The inhibition constants of this scFv fragment were determined as described in under “Experimental Procedures”: $K_i$ values were determined as $5.7 \times 10^{-8}$ M and $4.7 \times 10^{-5}$ M for the short V9C peptide and for the extended G19K peptide, respectively.

To assess the ability of the scFv to interact with the receptor, immunocytochemical experiments were performed on CHO M2Ach-R transfected cells. Fig. 2b shows the presence of a specific membrane and cytoplasmic labeling when using the scFv B8E5 fragment. No specific labeling could be observed on CHO untransfected cells, CHO transfected with M1Ach-R and M3Ach-R, and on CHO transfected with the M2Ach-R treated with an scFv control.

Pharmacological Characterization of the scFv Fragment—Next we determined if the scFv construction had pharmacological properties on the M2Ach-R. Activation of the M2Ach-R induces a decrease of intracellular cAMP mediated by the G_i protein (23). CHO M2Ach-R transfected cells were pretreated with 1 μM of forskolin, which activates adenylyl cyclase. The decrease of intracellular measured cAMP thus will be directly correlated with activation of the M2Ach-R. CHO M2Ach-R transfected cells stimulated with forskolin were treated with different scFv concentrations in the presence or absence of carbachol (30 nM). Interestingly, the B8E5 scFv fragments were able to significantly increase the forskolin-induced accumulation of cAMP in a dose-dependent manner (Fig. 3a). This is the main characteristic of inverse agonists (see Ref. 24 for review). Moreover, Fig. 3b shows that scFv B8E5 was able to inhibit the activation of the M2 muscarinic receptor by carbachol in a dose-dependent manner. Also, a fixed concentration of 25 nM scFv seems to inhibit in a non-competitive manner the effect of carbachol (Fig. 3c). These results were confirmed in vitro by measuring the beating rate of neonatal rat cardiomyocytes stimulated by

---

Fig. 5. Physiological effects of the scFv B8E5 on mouse heart, in vivo cardiac physiology measurements. Mean (±S.E.) of the variation of the cardiac rhythm at different time after intravenous injection of scFv control and scFv B8E5 alone (a), carbachol (0.1 mg/kg) with and without scFv B8E5 (b), and isoproterenol (2 mg/kg) alone or in combination with scFv B8E5 (c) reported on the cardiac rhythm normalized at $t = 0$. The integrals of each graph were compared at $p < 0.05$ in a paired matched Student's t test.
carbachol (Fig. 4). The basal beating rate of the cardiomyocytes as well as the carbachol dose-response curve were increased. In view of the fact that the carbachol dose-response curve in presence of scFv only showed a decrease in the maximal response not present with the 9C2 scFv control (data not shown), it typically represents a non-competitive inhibition of the carbachol effect. We thus conclude through two different experiments that the scFv acts in a non-competitive manner.

**Physiological Characterization of the scFv Fragment**—To investigate the possible in vivo effects of the scFv B8E5 on the heart, we injected the scFv construction in mice alone or combined with the muscarinic receptor agonist carbachol (0.1 mg/kg) or the β-adrenoreceptor agonist isoproterenol (2 mg/kg). The animals had a comparable heart rate before the different administrations (data not shown). ScFv injected alone induced a significant increase ($p = 0.012$) of the heart rate compared with the NaCl treatment at the beginning of the recording (Fig. 5a).

Injection of carbachol (0.1 mg/kg intravenously injected) induced a marked decrease of the heart rate. This effect was
significantly blunted ($p = 0.041$) in the presence of scFv B8E5 (Fig. 5b).

Isoproterenol (2 mg/kg), a $\beta$-agonist, induced a marked increase of the heart rate. This increase was significantly reduced ($p = 0.042$) in the presence of scFv B8E5 (Fig. 5c).

**DISCUSSION**

Most of the neurotransmitter receptors belong to the family of G protein-coupled receptors representing one of the main targets of cardiovascular and neurological drugs. The pharmacological existence of subfamilies of these receptors was first assessed by showing that the same neurotransmitters had different effects on different tissues. Cloning, sequencing, and expressing molecules, coded by different genes but recognizing the same neurotransmitters, highlighted this molecular diversity. In view of the putative structure of these proteins, the localization of the neurotransmitters in an intramembrane pocket was suggested. This fact only allows a limited amount of variability to dock different agonist and antagonists. On the other hand, the constancy of the pharmacophore pocket between members of the same family could explain the difficulty to design and synthesize molecules with an exclusive specificity for one of the receptor subtypes. In contrast, the extracellular domains of receptors of the same family can vary more widely which suggests the possibility to raise antibodies possessing the single specificity intended by the pharmacologists.

Drug discovery based on immunological reagents was already forwarded more than 20 years ago, but only recently because of the expansion of biotechnological tools could it be considered as a realistic goal. Indeed, recent results have shown that such approach could lead to functional peptides derived from antibodies directed against cell receptors (25). The finding that autoantibodies against G protein-coupled receptors were present in and responsible for different cardiovascular diseases prompted us to use a similar approach for the development of antibody fragments of low molecular weight interfering with this family of receptors.

Cloning and sequencing of the variable regions of the B8E5 monoclonal antibody in comparison with the corresponding germ line showed 45% and 42.6% variability, respectively, for the heavy chain and for the light chain. The sequence of the variable part of the heavy chain corresponded for 84% to that of the Protein Data Bank accession code 1IIF (26) (lgG 2A Fab fragment complexed with a 7-mer peptide from influenza virus hemagglutinin HA1-(101–107)), whereas the sequence of the light chain corresponded for 94.7% to that of the Protein Data Bank accession code 2MCP (27) (phosphocholine binding immunoglobulin Fab fragment McPC603). The high similarity of the scFv fragment with antibody combining sites of a known three-dimensional structure allowed us to construct a realistic model of the scFv fragment in *silico* (Fig. 6). The percents of $\phi$ and $\psi$ angles core region occupancy are for the $V_{H}$ and for the $V_{L}$ of 74.6% and 73.9%, respectively.

The physicochemical parameters of the epitope-scFv interaction as measured by surface plasmon resonance allowed us to confirm that the scFv fragment had similar binding properties as the Fab fragment of the B8E5 antibody. Difference in inhibition constants for the long (G19K) and the short (V9C) peptides is certainly caused by a lesser accessibility of the epitope for the antibody fragment on the long peptide. The same observation was made previously with the monoclonal antibody (8). Active concentration calculation of purified scFv shows that 100% of the purified recombinant proteins are able to interact with their antigen. Protein L used for the purification of the scFv interacted with the VL $\kappa$ chain (28, 29) in a conformational way. The 100% of activity of purified scFv thus can be explained by the fact that only correctly folded recombinant proteins can also interact with protein L. A cytochemistry experiment showed a specific labeling of membrane and of the cytoplasm of M2Ach-R transfected cells compared with untransfected cells and cells transfected with two other subtypes of muscarinic receptors. These results are in accordance with the data presented in Table II, which show that the recognized epitope VRTVE is different in the other muscarinic receptors subtype. Indeed, the V residue at the Nter portion of the epitope, important for the interaction peptide/antibody (8), is not present in the other subtypes of muscarinic receptors. These results confirm the high specificity of this antibody fragment on the M2Ach-R.

In our previous studies, an scFv fragment of an antibody directed against the second extracellular loop of the $\beta_{2}$ adrenergic receptor was shown to have an inverse agonist activity (9). We supposed that monovalency of the anti-M2Ach-R antibody fragment compared with the bivalency of the partial agonist monoclonal antibody B8E5 led to the same properties. To directly check the pharmacological activity of this recombinant protein, we studied the accumulation of cAMP in M2R-Ach CHO transfected cells in the presence of forskolin with and without carbachol. The scFv fragments not only inhibited the cAMP decrease induced by carbachol, but they also increased the cAMP accumulation induced by forskolin. This means that the scFv fragments behave as inverse agonists, i.e., molecules specifically recognizing the resting conformation of the receptor and shifting the active $\rightarrow$ resting conformational equilibrium to the right. A dose-response carbachol curve in the presence of scFv suggested that carbachol inhibition was non-competitive, suggesting an allosteric modulation of the receptor.

The scFv fragment was able to increase the spontaneous beating rate of neonatal rat cardiomyocytes in culture. We previously checked the 100% identity between the sequence of the second extracellular loop of the M2Ach-R from human and rat. The scFv fragment also blocked the effect on the same cells of the muscarinic agonist carbachol. This effect did not shift the carbachol dose-response curve to higher agonist concentrations but decreased the maximally obtained response. These results confirm that the scFv fragment blocks the accessibility of the pharmacophore pocket in a non-competitive manner or allosterically prevent the conformation transition from inactive to active state of the receptor.

This antibody fragment is able to decrease parasympathetic activity via its action on the M2Ach muscarinic receptor (no difference of sequence can be observed between the second extracellular loop of rat and human) and thus to induce an increase of the heart rate from $t = 1$ to $t = 10$.

The antibody fragment is also able to block the action of carbachol *in vivo*. These results were similar to that observed *in vitro*, physiologically confirming the biochemical inverse agonist activity of the fragment. Moreover, isoproterenol treatment combined with scFv showed a smaller increase of the heart rate than for isoproterenol alone. This phenomenon was observed with low doses of pirenzepine, an inverse agonist of the M2 muscarinic receptor (30), combined with isoprenaline in healthy human volunteers (31).

To summarize, we have completely characterized a polypeptide with a specific inverse agonist activity on the M2 muscarinic receptor. It is the second example of a G protein-coupled receptor inverse agonist shifting by an allosteric mechanism the receptor to its resting conformation. The structural model that we obtained from the scFv fragment could help us to design shorter peptide fragments with similar properties.

**Acknowledgment**—We thank Dr. M. Waelbroeck (Faculté de Médecine, Université Libre de Bruxelles, Belgium) for providing the CHO M1Ach-R, M2Ach-R, and M3Ach-R transfected cells.
REFERENCES

1. Christopoulos, A. (2002) *Nat. Rev. Drug Discov.* **1**, 198–210
2. Wallukat, G., and Wollenberger, A. (1987) *Biomed. Biochim. Acta* **46**, S634–S639
3. Limas, C. J., Goldenberg, I. F., and Limas, C. (1989) *Circ. Res.* **64**, 97–103
4. Borda, E., Pascual, J., Cossio, P., De La Vega, M., Arana, R., and Sterin-Borda, L. (1984) *Clin. Exp. Immunol.* **57**, 679–686
5. Borda, E. S., and Sterin-Borda, L. (1996) *Int. J. Cardiol.* **54**, 149–156
6. Elies, R., Ferrari, I., Wallukat, G., Lebesgue, D., Chiale, P., Elizari, M., Rosenbaum, M., Hoebeke, J., and Levin, M. J. (1996) *J. Immunol.* **157**, 4203–4211
7. Elies, R., Fu, L. X., Eftekhari, P., Wallukat, G., Schulze, W., Granier, C., Hjalmarson, A., and Hoebeke, J. (1998) *Eur. J. Biochem.* **251**, 659–666
8. Peter, J. C., Eftekhari, P., Billiald, P., Wallukat, G., and Hoebeke, J. (2003) *J. Biol. Chem.* **278**, 36740–36747
9. Neimark, J., and Briand, J. P. (1993) *Pept. Res.* **6**, 219–228
10. Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P., and Winter, G. (1991) *Nucleic Acids Res.* **19**, 4133–4137
11. Mousli, M., Devaux, C., Rochat, H., Goyffon, M., Billiald, P. (1998) *FEBS Lett.* **458**, 67–74
12. Porter, R. R. (1959) *Biochem. J.* **73**, 119–126
13. Mijares, A., Lebesgue, D., Wallukat, G., and Hoebeke, J. (2000) *Mol. Pharmacol.* **58**, 373–379
14. Richalet-Secordel, P. M., Rauffer-Bruyere, N., Christensen, L. L., Ofenloch-Haechtle, B., Seidel, C., and Van Regenmortel, M. H. (1997) *Anal. Biochem.* **249**, 165–173
15. Buckley, N. J., Bonner, T. I., Buckley, C. M., and Brann, M. R. (1989) *Mol. Pharmacol.* **35**, 469–476
16. Aubrey, N., Devaux, C., di Luccio, E., Goyffon, M., Rochat, H., and Billiald, P. (2001) *Biol. Chem.* **382**, 1621–1628
17. Wallukat, G., Wollenberger, A., Morwinski, R., and Pitschner, H. F. (1995) *J. Mol. Cell. Cardiol.* **27**, 397–406
18. Wallukat, G., Wollenberger, A., Morwinski, R., and Pitschner, H. F. (1995) *J. Mol. Cell. Cardiol.* **27**, 397–406
19. Eftekhari, P., Roegel, J. C., Lexouala, F., Fischmeister, R., Imbs, J. L., and Hoebeke, J. (2001) *Eur. J. Immunol.* **31**, 573–579
20. Chaves, A. A., Dech, S. J., Nakayama, T., Hamlin, R. L., Bauer, J. A., and Carnes, C. A. (2003) *Life Sci.* **72**, 2401–2412
21. Carroll, W. L., Mendel, E., and Levy, S. (1988) *Mol. Immunol.* **25**, 991–995
22. Lei, S. P., Lin, H. C., Wang, S. S., Callaway, J., and Wilcox, G. (1987) *J. Bacteriol.* **169**, 4379–4383
23. Sunahara, R. K., Dessauer, C. W., and Gilman, A. G. (1996) *Annu. Rev. Pharmacol. Toxicol.* **36**, 481–489
24. Daeflner, L., and Landry, Y. (2000) *Fundam. Clin. Pharmacol.* **14**, 73–87
25. Bes, C., Brient-Longuet, L., Cerruti, M., De Berardinis, P., Devauchelle, G., Devaux, C., Granier, C., Charles, T., and DeBerardinis, P. (2001) *FEBS Lett.* **508**, 67–74
26. Schulze-Gahmen, U., Rini, J. M., and Wilson, I. A. (1993) *J. Mol. Biol.* **234**, 1098–1118
27. Sato, Y., Cohen, G. H., Padlan, E. A., and Davies, D. R. (1986) *J. Mol. Biol.* **190**, 593–604
28. Akerstrom, B., and Bjorck, L. (1989) *J. Biol. Chem.* **264**, 19740–19746
29. Graille, M., Stura, E. A., Housden, N. G., Beckingham, J. A., Bottomley, S. P., Beale, D., Tausig, M. J., Sutton, B. J., Gore, M. G., and Charbonnier, J. B. (2001) *Structure (Lond.*) **9**, 679–687
30. Daeflner, L., Schmidlin, F., Gies, J. P., and Landry, Y. (1999) *Br. J. Pharmacol.* **126**, 1246–1252
31. Brodde, O. E., Kunschak, U., Becker, K., Ruter, F., Poller, U., Jakubetz, J., Radke, J., and Zerkowski, H. R. (1998) *J. Clin. Invest.* **101**, 471–478
32. Halle, W., and Wollenberger, A. (1970) *Am. J. Cardiol.* **25**, 292–299